Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
Status:
Withdrawn
Trial end date:
2020-11-07
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing
patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced
ultrasound may provide detailed imaging of the tumor arteries after the injection of a
contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit
in the tumor.